Reina Madre Mexico City: The NCT Facility String Is Not the COFEPRIS File

Reina Madre in Mexico City, Mexico, is a separate named facility string in the public record.

General information, not legal or regulatory advice. This page cites a public ClinicalTrials.gov facility row. It does not claim that bioaccess® ran the study, that the facility is a client, or that the registry record is a first-in-human device authorization.

When a sponsor searches a facility name, the search result can look like a complete clinical-development answer. It is not. A site can contribute investigators, rooms, coordinators, recruitment, and protocol-specific operations. The sponsor still needs the study strategy, contracts, ethics submission, data systems, monitoring, safety reporting, insurance, and the applicable regulatory file. A facility string is not a CRO.

The public record used here is ClinicalTrials.gov study NCT06581068. The record describes an industry-sponsored study involving IVF-lab automation and lists facilities in Mexico City. The registry is evidence that the facility string appears in a public study record. It is not evidence of a bioaccess® engagement, an endorsement, a completed outcome, or a regulatory clearance.

What the facility can do

• Assess whether the protocol fits its patient flow, laboratory capability, staffing, and local research procedures.
• Discuss investigator interest, site feasibility, visit logistics, and institutional review steps.
• Provide site-specific costs and operational requirements for the work it will physically perform.

What the facility row does not establish

• It does not establish that the facility is the sponsor, CRO, importer of record, insurer, or regulatory applicant.
• It does not establish the identity or qualifications of a principal investigator beyond whatever the public record itself displays.
• It does not establish that a treatment-validation study is a first-in-human medical-device study.
• It does not replace a protocol-specific feasibility review, agreement, or regulatory assessment.

Mexico City is a site decision, not the whole start-up plan

For work in Mexico, a sponsor should separate institutional ethics and operational planning from the COFEPRIS pathway. Trial authorization, investigational import, insurance, monitoring, electronic data capture, adverse-event reporting, and the later sanitary registration question are different workstreams. A site email can help answer a local feasibility question. It cannot by itself open the national file or create a quality system.

bioaccess® can assess the country and protocol fit, coordinate the regulatory and site-start-up work, and keep the operating responsibilities explicit. The correct sequence is to confirm the protocol, identify the required site capabilities, document feasibility, agree the scope, and then activate the facility if it fits. The page is not a claim that either named facility is a signed bioaccess® partner.

About the registry record

NCT06581068 is cited here because it is the public source for the facility association. Registry records can change, use facility aliases, and describe a study purpose that is not the same as a sponsor’s later device-regulatory plan. Read the current record directly before making a decision. Do not infer clinical performance, patient outcomes, regulatory status, or commercial availability from a facility name.

Frequently asked questions

Did bioaccess® run NCT06581068?

No. This page cites a public facility row only. We will not invent a client relationship, investigator role, outcome, or sponsor claim.

Can a sponsor contract the facility directly?

A sponsor can discuss site interest and local operations with a facility. That discussion is not a substitute for the CRO, regulatory, safety, data, insurance, and multi-country responsibilities the protocol may require.

Is this a regulatory approval?

No. A ClinicalTrials.gov listing is not COFEPRIS authorization, ethics approval, import permission, or sanitary registration.

What is the next step?

Start with a protocol-specific feasibility and country-fit review. Then define the regulatory, site, monitoring, data, safety, insurance, and import workstreams before activation.

bioaccess® does not name either facility as a signed partner here. We use the public record to answer a search, not to invent a relationship.

Julio G. Martinez-Clark, CEO · bioaccess®